newsfilter
← Latest News
Business Wire·

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for